ZA925B - Hyperglycemic compositions - Google Patents

Hyperglycemic compositions

Info

Publication number
ZA925B
ZA925B ZA925A ZA925A ZA925B ZA 925 B ZA925 B ZA 925B ZA 925 A ZA925 A ZA 925A ZA 925 A ZA925 A ZA 925A ZA 925 B ZA925 B ZA 925B
Authority
ZA
South Africa
Prior art keywords
hyperglycemic
compositions
hyperglycemic compositions
Prior art date
Application number
ZA925A
Inventor
Andrew Young
Young Andrew
Garth James Smith Cooper
James Smith Cooper Garth
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of ZA925B publication Critical patent/ZA925B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA925A 1991-01-10 1992-01-02 Hyperglycemic compositions ZA925B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/640,478 US5234906A (en) 1991-01-10 1991-01-10 Hyperglycemic compositions

Publications (1)

Publication Number Publication Date
ZA925B true ZA925B (en) 1993-03-31

Family

ID=24568421

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA925A ZA925B (en) 1991-01-10 1992-01-02 Hyperglycemic compositions

Country Status (8)

Country Link
US (1) US5234906A (en)
EP (1) EP0525158A4 (en)
JP (1) JPH05505626A (en)
AU (1) AU641855B2 (en)
CA (1) CA2076658C (en)
SG (1) SG43866A1 (en)
WO (1) WO1992011862A1 (en)
ZA (1) ZA925B (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2077265A1 (en) * 1991-01-10 1992-07-11 Andrew Young Amylin activity assays
HU222249B1 (en) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Process for producing amyline antagonistic peptide derivatives and pharmaceutical preparatives containing them
DE69221725T2 (en) * 1991-05-24 1997-12-18 Amylin Pharmaceuticals, Inc., San Diego, Calif. COMPOSITION CONTAINING AMYLIN OR AMYLINANALOG, WHICH ALSO CONTAINS INSULIN FOR THE TREATMENT OF ANOREXIA AND RELATED CONDITIONS
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
ATE205854T1 (en) * 1991-11-19 2001-10-15 Amylin Pharmaceuticals Inc PEPTIDES AS AMYLIN AGONISTS AND THEIR USE
CZ69596A3 (en) * 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5763200A (en) * 1995-05-12 1998-06-09 Biomeasure, Incorporated Inhibition of amylin release
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5677279A (en) * 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO2000078805A1 (en) * 1999-06-18 2000-12-28 Protemix Corporation Limited Peptide having preptin functionality
EP1251867A4 (en) 2000-02-04 2004-12-08 Unigene Lab Inc Nasal calcitonin formulations
WO2002043566A2 (en) * 2000-11-28 2002-06-06 Baum Martin G Devices and methods for treating low blood sugar levels
US20030208113A1 (en) * 2001-07-18 2003-11-06 Mault James R Closed loop glycemic index system
US20040038861A1 (en) * 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
US20040009976A1 (en) * 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
US8168233B2 (en) * 2002-10-18 2012-05-01 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
CA2509755A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
RU2360671C2 (en) * 2003-07-01 2009-07-10 Эссентис Аб Application of alpha-ketoglutaric acid for treatment of undernutrition or condition with high-glucose plasma level
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
CN1961000B (en) 2004-02-11 2011-05-04 安米林药品公司 Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2009048462A1 (en) 2007-10-09 2009-04-16 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2597649A1 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US7879794B2 (en) 2005-03-31 2011-02-01 Amylin Pharmaceuticals, Inc. Methods for controlling binge eating disorders
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
JP5312054B2 (en) 2006-03-15 2013-10-09 ノボ・ノルデイスク・エー／エス Mixture of amylin and insulin
US20090181890A1 (en) * 2006-03-31 2009-07-16 Amylin Pharmaceuticals , Inc. Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
WO2007114838A1 (en) 2006-03-31 2007-10-11 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
US8536120B2 (en) * 2006-04-28 2013-09-17 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
US20080076721A1 (en) * 2006-09-25 2008-03-27 Sal Abraham Use of branched chain fatty acid amino acid salts and compositions thereof
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2203741B1 (en) 2007-10-25 2023-05-10 Dexcom, Inc. Systems and methods for processing sensor data
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
SG11201707286UA (en) 2015-03-18 2017-10-30 Zealand Pharma As Amylin analogues
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
CN110366424B (en) 2016-12-27 2024-05-24 阿道恰公司 Composition in the form of an injectable aqueous solution comprising an amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
PL3658115T3 (en) 2017-07-27 2022-08-08 Adocia Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor
FR3082426A1 (en) 2018-06-14 2019-12-20 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AT LEAST HUMAN INSULIN A21G AND A PRANDIAL ACTION GLUCAGON SUPPRESSOR
FR3083089A1 (en) 2018-06-29 2020-01-03 Adocia PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS
FR3083086A1 (en) 2018-06-29 2020-01-03 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
CA3084699A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analog and a co-polyamino acid
US20190275108A1 (en) 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a co-polyamino acid
EP3723728A1 (en) 2017-12-07 2020-10-21 Adocia Injectable solution with a ph of 7 comprising at least one basal insulin with a pi of between 5.8 and 8.5 and a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals
CN111565710A (en) 2017-12-07 2020-08-21 阿道恰公司 Composition in the form of an injectable aqueous solution comprising an amylin, an amylin receptor agonist or an amylin analog, and a copolyaminoacid
SG11202005322RA (en) 2017-12-07 2020-07-29 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
FR3083085B1 (en) 2018-06-29 2020-10-02 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND A CO-POLYAMINOACID
FR3084586B1 (en) 2018-08-03 2020-11-06 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS
IL292863A (en) 2019-11-13 2022-07-01 Amunix Pharmaceuticals Inc Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
EP3915572A1 (en) 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
EP3915571A1 (en) 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27885A (en) * 1985-01-22 1986-07-23 Novo Industri As PREPARATION OF PEPTIDES
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions

Also Published As

Publication number Publication date
EP0525158A1 (en) 1993-02-03
US5234906A (en) 1993-08-10
EP0525158A4 (en) 1993-08-25
WO1992011862A1 (en) 1992-07-23
CA2076658C (en) 1996-09-03
AU641855B2 (en) 1993-09-30
CA2076658A1 (en) 1992-07-11
SG43866A1 (en) 1997-11-14
JPH05505626A (en) 1993-08-19
AU1328692A (en) 1992-08-17

Similar Documents

Publication Publication Date Title
SG43866A1 (en) Hyperglycemic compositions
GB9102579D0 (en) Compositions
GB9005856D0 (en) Compositions
ZA92342B (en) Lice-repellant compositions
GB9015822D0 (en) Compositions
GB9114099D0 (en) Compositions
GB9101592D0 (en) Compositions
GB9015892D0 (en) Compositions
GB9101655D0 (en) Compositions
GB9121219D0 (en) New compositions
EP0452632A3 (en) Dichloro-pentafluoropropanes-containing compositions
GB9101654D0 (en) Compositions
GB9004832D0 (en) Compositions
HU900262D0 (en) Oralhygenic compositions
GB9116920D0 (en) Compositions
GB9117418D0 (en) Compositions
GB9119673D0 (en) Compositions
GB9123026D0 (en) Compositions
GB9123044D0 (en) Compositions
GB9117211D0 (en) Compositions
GB9116923D0 (en) Compositions
GB9116922D0 (en) Compositions
GB9110111D0 (en) Compositions
GB9105197D0 (en) Compositions
GB9102881D0 (en) Compositions